These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28440011)

  • 1. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.
    Abdi A; Eckhardt CL; van Velzen AS; Vuong C; Coppens M; Castaman G; Hart DP; Hermans C; Laros-van Gorkom B; Leebeek FWG; Mancuso ME; Mazzucconi MG; McRae S; Oldenburg J; Male C; van der Bom JG; Fijnvandraat K; Gouw SC;
    J Thromb Haemost; 2021 Sep; 19(9):2171-2181. PubMed ID: 34107158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
    Gouw SC; van den Berg HM; Fischer K; Auerswald G; Carcao M; Chalmers E; Chambost H; Kurnik K; Liesner R; Petrini P; Platokouki H; Altisent C; Oldenburg J; Nolan B; Garrido RP; Mancuso ME; Rafowicz A; Williams M; Clausen N; Middelburg RA; Ljung R; van der Bom JG;
    Blood; 2013 May; 121(20):4046-55. PubMed ID: 23553768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.
    Kempton CL; Soucie JM; Miller CH; Hooper C; Escobar MA; Cohen AJ; Key NS; Thompson AR; Abshire TC
    J Thromb Haemost; 2010 Oct; 8(10):2224-31. PubMed ID: 20704648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
    J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.
    Eckhardt CL; Menke LA; van Ommen CH; van der Lee JH; Geskus RB; Kamphuisen PW; Peters M; Fijnvandraat K
    J Thromb Haemost; 2009 Jun; 7(6):930-7. PubMed ID: 19548904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.
    Halimeh S; Bidlingmaier C; Heller C; Gutsche S; Holzhauer S; Kenet G; Kurnik K; Manner D; Iorio A; Nowak-Göttl U
    Biomed Res Int; 2013; 2013():901975. PubMed ID: 24199202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.
    Cannavò A; Valsecchi C; Garagiola I; Palla R; Mannucci PM; Rosendaal FR; Peyvandi F;
    Blood; 2017 Mar; 129(10):1245-1250. PubMed ID: 28034891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
    Sharathkumar A; Lillicrap D; Blanchette VS; Kern M; Leggo J; Stain AM; Brooker L; Carcao MD
    J Thromb Haemost; 2003 Jun; 1(6):1228-36. PubMed ID: 12871324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
    Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.
    Rosendaal FR; Nieuwenhuis HK; van den Berg HM; Heijboer H; Mauser-Bunschoten EP; van der Meer J; Smit C; Strengers PF; Briët E
    Blood; 1993 Apr; 81(8):2180-6. PubMed ID: 8471777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicohematologic Profile of Patients With Factor VIII Inhibitors: A Case Series.
    Singh N; Mishra P; Tyagi S; Pati HP; Mahapatra M; Seth T; Saxena R
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):246-50. PubMed ID: 25172870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.
    Lim MY; Nielsen B; Lee K; Kasthuri RS; Key NS; Ma AD
    J Thromb Haemost; 2014 Jun; 12(6):897-901. PubMed ID: 24702722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.